| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Type 2 Issues Articles
Cholesterol-Lowering Drug Lowers Risk of Diabetic Retinopathy Surgery
Researchers have found that fenofibrate, also known as Lofibra and TriCor, reduces the progression of diabetic retinopathy in humans. (Retinopathy occurs when the small blood vessels that supply the eye begin to leak and swell, resulting in progressive vision loss.)
To arrive at their findings, the researchers studied 9,795 type 2s between the ages of 50 and 75, half of whom received fenofibrate and the rest of whom received a placebo. After five years of follow-up, there was a 31 percent reduction in need for laser therapy to treat diabetic retinopathy in the fenofibrate patients. The researchers believe that fenofibrate may work its magic via an anti-inflammatory or antioxidant effect.
Like other fibrates, fenofibrate reduces bad cholesterol (LDL and VLDL), increases healthy HDL levels, and lowers triglycerides, reducing the accumulation of fat inside artery walls. Fibrates activate PPARs (peroxisome proliferator-activated receptors), which cause transcription of genes that help lipid metabolism. They also appear to have a beneficial effect on insulin resistance associated with the metabolic syndrome.
Interestingly, fibrates are structurally and pharmacologically related to thiazolidinediones, a class of diabetes drug that also acts on PPARs.
Sources: MedlinePlus, November 2007; Wikipedia
Categories: Eye Care (Retinopathy), Type 1 Issues, Type 2 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
Dec 22, 2007 -
Email to a Friend
Send a link to this page to your friends and colleagues.